PZ CORMAY: Up to 2016. Company spent on investment of 57.2 million zł – parquet

Janusz Płocica, CEO of PZ CORMAY, hoping for a rapid improvement in business performance.

Source: Fotorzepa

The author: Andrew Cynka

Manufacturer of diagnostic reagents and distributor of medical equipment on Friday published a prospectus relating to the issuance of series K shares with a price of 1.5 zł. The Company intends to raise from the market 46.3 million zł. Subscriptions for shares will take place from 3 to 17 August. The offer will conduct Trigon DM.

– Starting on just a public offer of PZ CORMAY is necessary to ensure that the company has entered the path of dynamic growth based on the marketed their own analyzers – Equisse, Hermes and BlueBox. Money raised from the issue of series K shares will be used just to complete those carried out for many years key projects. The total investment to be incurred in this and next year is about 57.2 million zł. It will be awaited by us and the proverbial icing on the market and lasting for a few years the investment process – says Janusz Plocica and CEO of PZ CORMAY.

The company wants to spend 6.7 million zł to complete work on the biochemical analyzer Equisse , 1.9 million zł for completion of work on a hematology analyzer Hermes, Sr., 5.4 million zł for completion of work on a hematology analyzer Hermes Junior and 10.5 million zł for work on the analyzer POCT-BlueBox. In addition, 15.9 million zł is expected to build a manufacturing and logistics center in Lublin and 16.8 million zł for its equipment.

The President points out that the positive impact of new products on the results will be visible right from the start of their sales in 2016. – both in revenues and margins. – It will rapidly increase in the coming years and it is these products will determine a significant increase in performance and value of the company – says Płocica.

At the end of 2013. Value of the global market for IVD (in vitro diagnostics) was estimated at 54.5 billion USD. Forecasts of experts assume that in 2018. Grow to about 69.3 billion USD. In Poland expenditure on IVD are estimated at 281 million euros. In 2013. Market increased by 7 percent. In Europe, the average per person is spent on IVD 18 euros. On the Vistula River is only 7.3 euros.

– We want the best use of this potential, and owning analyzers great fit in with market trends and our distributors in dozens of countries around the world are looking forward to not expect – concludes president.

At Friday’s session before the hour. 16 share price fell by 3.6 per cent., To 1.88 zł. Since January capitalization decreased by 37 percent.